Upinitatug rilsodotin

瑞度尤匹妥塔单抗

Report date: 2024/02/05 14:45:26

Base Information

Drug NameUpinitatug rilsodotin
Drug Alias NameUpifitamab rilsodotin瑞索尤匹菲妥单抗XMT-1536
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > Non-cleavable thioether linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > AF-HPA payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionSodium-dependent phosphate transport protein 2B inhibitors
TargetsSodium-dependent phosphate transport protein 2B
Therapy Area/IndicationsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMersana Therapeutics IncAdimab LLC
China Registration ClassN/A

Develop Information

Active CompaniesMersana Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A